NCT06993740 - Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

May 26, 2026

Study Completion Date

August 22, 2026

Conditions

Flap MonitoringInflammationThrombosisOxidative StressGlycocalyxAnesthesiaSurgeryFlap IschemiaFlap NecrosisFlap Failure Risk FactorsMicrosurgery

Interventions

DRUG

NaCl 0,9%

NaCl 0.9% continuous intravenous infusion during microsurgical reconstruction surgery in cancer patients, started after anesthesia induction and maintained intraoperatively and up to 48 hours postoperatively.

DRUG

Dexmedetomidine

Dexmedetomidine continuous intravenous infusion during microsurgical reconstruction surgery in cancer patients, started after anesthesia induction and maintained intraoperatively and up to 48 hours postoperatively, titrated to maintain target sedation and hemodynamic stability.

Trial Locations (2)

11420

NOT_YET_RECRUITING

Dharmais National Cancer Center Hospital, Jakarta

RECRUITING

Dharmais National Cancer Center Hospital, Jakarta

All Listed Sponsors

lead

Dharmais National Cancer Center Hospital

OTHER_GOV